Six drug companies have shown no sign so far of acquiescing to the federal government’s order on Monday to immediately resume 340B pricing on their products dispensed by contract pharmacies.
340B covered entities yesterday reported seeing no evidence that Eli Lilly, Astra Zeneca, Sanofi, Novartis, Novo Nordisk, or United Therapeutics have restored or are making plans to restore 340B prices on medicines that entities buy and have shipped to outside pharmacies for dispensing. A consultant learned via a major wholesaler that manufacturers’ blocks on 340B pricing for drugs shipped to contract pharmacies are intact. The wholesaler has asked manufacturers how they intend to proceed in light of the government’s orders.
Six drug companies have shown no sign so far of acquiescing to the federal government’s order on Monday to immediately resume 340B pricing on their products dispensed by contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
